Natera (NASDAQ:NTRA) Insider Sells $4,179,780.44 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 17,806 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total transaction of $4,179,780.44. Following the sale, the insider directly owned 177,591 shares of the company’s stock, valued at $41,687,711.34. This trade represents a 9.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

John Fesko also recently made the following trade(s):

• On Wednesday, January 21st, John Fesko sold 339 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $79,665.00.
• On Tuesday, October 28th, John Fesko sold 928 shares of Natera stock. The shares were sold at an average price of $191.46, for a total value of $177,674.88.
• On Monday, October 27th, John Fesko sold 781 shares of Natera stock. The stock was sold at an average price of $192.32, for a total value of $150,201.92.

Natera Stock Performance

Shares of NASDAQ:NTRA traded up $0.13 during midday trading on Thursday, reaching $242.91. 971,052 shares of the company’s stock traded hands, compared to its average volume of 950,311. Natera, Inc. has a one year low of $125.38 and a one year high of $256.36. The company has a market cap of $33.60 billion, a price-to-earnings ratio of -106.07 and a beta of 1.62. The stock has a 50 day moving average of $233.44 and a 200 day moving average of $190.60.

Natera (NASDAQ:NTRA) last issued its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.Natera’s quarterly revenue was up 34.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.26) EPS. Sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Trading of Natera

Institutional investors and hedge funds have recently modified their holdings of the company. Integrated Wealth Concepts LLC increased its stake in Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after buying an additional 96 shares in the last quarter. NewEdge Advisors LLC grew its position in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth raised its stake in Natera by 8.6% during the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC purchased a new position in Natera in the 2nd quarter worth approximately $298,000. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in Natera by 46.4% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 28,323 shares of the medical research company’s stock worth $4,582,000 after purchasing an additional 8,977 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on NTRA. Barclays raised their target price on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Piper Sandler increased their price target on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Guggenheim raised their price target on Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Stephens lifted their price objective on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Finally, Evercore ISI upped their price objective on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $245.50.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.